Skip to main content
SpringerLink
Log in

Biomarkers in Acute Severe Ulcerative Colitis

  • Chapter
  • First Online:
Book cover Biomarkers in Inflammatory Bowel Diseases

  • 641 Accesses

Abstract

This chapter will cover prognostic and predictive biomarkers in acute severe ulcerative colitis (ASUC) that have been used to predict steroid response/failure and salvage therapy response/failure. It will provide a clinical algorithm encompassing biomarkers to help guide clinical management as well as identify future directions for ongoing research.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2:1041–8.

    Article  CAS  Google Scholar 

  2. Dinesen LC, Walsh AJ, Protic MN, Heap G, Cummings F, Warren BF, et al. The pattern and outcome of acute severe colitis. J Crohns Colitis. 2010;4:431–7.

    Article  Google Scholar 

  3. Kaplan GG, Seow CH, Ghosh S, Molodecky N, Rezaie A, Moran GW, et al. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol. 2012;107:1879–87.

    Article  CAS  Google Scholar 

  4. Narula N, Marshall JK, Colombel JF, Leontiadis GI, Williams JG, Muqtadir Z, et al. Systematic review and meta-analysis: infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids. Am J Gastroenterol. 2016;111:477–91.

    Article  CAS  Google Scholar 

  5. Lynch RW, Lowe D, Protheroe A, Driscoll R, Rhodes JM, Arnott ID. Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit. Aliment Pharmacol Ther. 2013;38:935–45.

    Article  CAS  Google Scholar 

  6. Cesarini M, Collins GS, Ronnblom A, Santos A, Wang LM, Sjoberg D, et al. Predicting the individual risk of acute severe colitis at diagnosis. J Crohns Colitis. 2016;11:335–41.

    PubMed Central  Google Scholar 

  7. Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103–10.

    Article  CAS  Google Scholar 

  8. Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38:905–10.

    Article  CAS  Google Scholar 

  9. Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol. 1992;87:971–6.

    CAS  PubMed  Google Scholar 

  10. Ho GT, Mowat C, Goddard CJ, Fennell JM, Shah NB, Prescott RJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther. 2004;19:1079–87.

    Article  CAS  Google Scholar 

  11. Gibson DJ, Hartery K, Doherty J, Nolan J, Keegan D, Byrne K, et al. CRP/Albumin ratio: an early predictor of steroid responsiveness in acute severe ulcerative colitis. J Clin Gastroenterol. 2018;52(6):e48–52.

    Google Scholar 

  12. Jain S, Kedia S, Bopanna S, Sachdev V, Sahni P, Dash NR, et al. Faecal calprotectin and UCEIS predict short-term outcomes in acute severe colitis: prospective cohort study. J Crohns Colitis. 2017;11:1309–16.

    Article  Google Scholar 

  13. Choy MC, Boyd K, Burder R, Gorelik A, Nallas R, Horvath J, et al. P511 Early prediction of steroid failure in acute severe ulcerative colitis. J Crohns Colitis. 2018;12:S363–S.

    Article  Google Scholar 

  14. Singh S, Al-Darmaki A, Frolkis AD, Seow CH, Leung Y, Novak KL, et al. Postoperative mortality among patients with inflammatory bowel diseases: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2015;149:928–37.

    Article  Google Scholar 

  15. Randall J, Singh B, Warren BF, Travis SP, Mortensen NJ, George BD. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg. 2010;97:404–9.

    Article  CAS  Google Scholar 

  16. Van Assche G, D’Haens G, Noman M, Vermeire S, Hiele M, Asnong K, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003;125:1025–31.

    Article  Google Scholar 

  17. Williams JG, Alam MF, Alrubaiy L, Arnott I, Clement C, Cohen D, et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. Lancet Gastroenterol Hepatol. 2016;1:15–24.

    Article  Google Scholar 

  18. Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, et al. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut. 2018;67(2):237–43.

    Article  Google Scholar 

  19. Moskovitz DN, Van Assche G, Maenhout B, Arts J, Ferrante M, Vermeire S, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4:760–5.

    Article  CAS  Google Scholar 

  20. Christensen B, Goeppinger SR, Colman R, Siddiqui D, Yarur A, Hirsch A, Bochenek AA, Wichmann A, Sakuraba A, Cohen R, Rubin DT. P404. Calcineurin inhibitors are safe and effective for induction of remission in patients commencing vedolizumab for IBD. J Crohns Colitis. 2015;9:S281–S.

    Google Scholar 

  21. Cacheux W, Seksik P, Lemann M, Marteau P, Nion-Larmurier I, Afchain P, et al. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol. 2008;103:637–42.

    Article  CAS  Google Scholar 

  22. Aceituno M, Garcia-Planella E, Heredia C, Zabana Y, Feu F, Domenech E, et al. Steroid-refractory ulcerative colitis: predictive factors of response to cyclosporine and validation in an independent cohort. Inflamm Bowel Dis. 2008;14:347–52.

    Article  Google Scholar 

  23. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–76.

    Article  CAS  Google Scholar 

  24. Choy MC, Seah D, Faleck DM, Shah SC, Al-Khoury A, An YK, et al. P542 Infliximab salvage therapy in acute severe ulcerative colitis: a systematic review and meta-analysis. J Crohns Colitis. 2018;12:S379–S80.

    Article  Google Scholar 

  25. Brandse JF, Mathot RA, van der Kleij D, Rispens T, Ashruf Y, Jansen JM, et al. Pharmacokinetic features and presence of antidrug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol. 2016;14:251-8.e1–2.

    Article  Google Scholar 

  26. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841–5.

    Article  CAS  Google Scholar 

  27. Bitton A, Buie D, Enns R, Feagan BG, Jones JL, Marshall JK, et al. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol. 2012;107:179–94; author reply 95.

    Article  CAS  Google Scholar 

  28. Choy MC, Seah D, Gorelik A, An YK, Chen CY, Macrae FA, et al. Predicting response after infliximab salvage in acute severe ulcerative colitis. J Gastroenterol Hepatol. 2018;33(7):1347–52.

    Article  CAS  Google Scholar 

  29. Ho GT, Lee HM, Brydon G, Ting T, Hare N, Drummond H, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol. 2009;104:673–8.

    Article  CAS  Google Scholar 

  30. Mitrev N, Vande Casteele N, Seow CH, Andrews JM, Connor SJ, Moore GT, et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;46:1037–53.

    Article  CAS  Google Scholar 

  31. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010;59:49–54.

    Article  CAS  Google Scholar 

  32. Beswick L, Rosella O, Rosella G, Headon B, Sparrow MP, Gibson PR, et al. Exploration of predictive biomarkers of early infliximab response in acute severe colitis: a prospective pilot study. J Crohns Colitis. 2018;12:289–97.

    Article  Google Scholar 

  33. Brandse JF, van den Brink GR, Wildenberg ME, van der Kleij D, Rispens T, Jansen JM, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015;149:350–5.e2. LID - S0016-5085(15)00572-7 [pii] LID - 10.1053/j.gastro.2015.04.016 [doi].

    Article  CAS  Google Scholar 

  34. Patel P, Yarur A, Dalal S, Sakuraba A, Rubin DT, Hanauer SB, et al. Clinical response and complications are not associated with drug levels in patients with severe ulcerative colitis on IV cyclosporine induction therapy. Inflamm Bowel Dis. 2018;24:1291–7.

    Article  Google Scholar 

  35. Gilissen LP, Wong DR, Engels LG, Bierau J, Bakker JA, Paulussen AD, et al. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy. J Crohns Colitis. 2012;6:698–707.

    Article  Google Scholar 

  36. Adedokun OJ, Sandborn WJ, Feagan BG, Rutgeerts P, Xu Z, Marano CW, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014;147:1296–307.e5.

    Article  CAS  Google Scholar 

  37. Olsen T, Goll R, Cui G, Christiansen I, Florholmen J. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis. Cytokine. 2009;46:222–7.

    Article  CAS  Google Scholar 

  38. Yarur AJ, Jain A, Sussman DA, Barkin JS, Quintero MA, Princen F, et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut. 2016;65(2):249–55.

    Article  Google Scholar 

  39. Dahlen R, Magnusson MK, Bajor A, Lasson A, Ung KA, Strid H, et al. Global mucosal and serum cytokine profile in patients with ulcerative colitis undergoing anti-TNF therapy. Scand J Gastroenterol. 2015;50(9):1118–26.

    Article  Google Scholar 

  40. Jurgens M, Laubender RP, Hartl F, Weidinger M, Seiderer J, Wagner J, et al. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol. 2010;105:1811–9.

    Article  Google Scholar 

  41. Daniel F, Loriot MA, Seksik P, Cosnes J, Gornet JM, Lemann M, et al. Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis. Inflamm Bowel Dis. 2007;13:19–23.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Austin Hospital, Melbourne, VIC, Australia

    Matthew C. Choy MBBS, BMedSci, FRACP, Dean Seah MD(Distinct), BBiomed & Peter De Cruz MBBS, PhD, FRACP

  2. Department of Gastroenterology, St Vincent’s Hospital, Fitzroy, VIC, Australia

    Matthew C. Choy MBBS, BMedSci, FRACP

  3. Department of Medicine, Austin Academic Centre, University of Melbourne, Melbourne, VIC, Australia

    Matthew C. Choy MBBS, BMedSci, FRACP

  4. Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia

    Peter De Cruz MBBS, PhD, FRACP

Authors
  1. Matthew C. Choy MBBS, BMedSci, FRACP
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dean Seah MD(Distinct), BBiomed
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter De Cruz MBBS, PhD, FRACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. St Vincent’s Hospital, The University of Melbourne, Melbourne, VIC, Australia

    Nik Sheng Ding

  2. Austin Health, The University of Melbourne, Melbourne, VIC, Australia

    Peter De Cruz

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Choy, M.C., Seah, D., De Cruz, P. (2019). Biomarkers in Acute Severe Ulcerative Colitis. In: Sheng Ding, N., De Cruz, P. (eds) Biomarkers in Inflammatory Bowel Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-11446-6_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-11446-6_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-11445-9

  • Online ISBN: 978-3-030-11446-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation